- cafead Nov 30, 2023 at 10:42: AM
via The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal.
This time, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere, which won FDA accelerated approval about a year ago.
article source
This time, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere, which won FDA accelerated approval about a year ago.
article source